Ovarian Cancer: A Short, Brief Review

DR. R.P.PATANGE, Professor, Department of Obstetrics and Gynecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University",Karad – 415110, Maharashtra

DR.ASHUTOSH BAHULEKAR, Assistant Professor, Department of Obstetrics and Gynecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University",Karad – 415110, Maharashtra

DR.ARUSHI RAINA, Resident, Department of Obstetrics and Gynecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University",Karad – 415110, Maharashtra

Abstract

Ovarian cancer is a terrible illness that still presents substantial obstacles to early detection and efficient treatment. In-depth information about ovarian cancer's epidemiology, risk factors, pathophysiology, clinical manifestation, diagnosis, and treatment choices is provided in this article.

Ovarian cancer is more common in some communities than others, and there are a number of risk factors. An elevated risk has been linked to advanced age, family history, reproductive variables, hormonal factors, genetic alterations, and environmental exposures. Complex molecular changes, including as genetic and epigenetic changes, modifications to signaling pathways, and deregulation of tumor suppressor genes and oncogenes, all play a role in the pathogenesis of ovarian cancer.

Ovarian cancer's clinical presentation might be hazy, which delays diagnosis. There are many diagnostic procedures, such as imaging methods and biomarker testing, yet it is still difficult to detect diseases accurately and quickly.

Surgical removal of the malignancy, chemotherapy, targeted therapies, and immunotherapies are available as treatments for ovarian cancer. The tumor's features and stage influence the therapy option. Recent developments in therapeutic approaches, like the application of PARP inhibitors and immunotherapies, have demonstrated promise in terms of improving results.

The management of ovarian cancer still faces difficulties, despite advances. Ongoing studies concentrate on strengthening early detection, creating better treatments, and enhancing

patient outcomes. This review offers a thorough overview of ovarian cancer in an effort to advance knowledge of this difficult condition and direct future study and therapeutic practice.

Keywords: ovarian cancer, epidemiology, risk factors, pathogenesis, clinical presentation, diagnosis, treatment

Introduction

Ovarian cancer is a serious health issue that affects women all over the world. With more than 300,000 new cases identified each year, it is the seventh most common cause of cancer-related deaths in women [1]. Ovarian cancer has a high mortality rate that can be related to late-stage detection and few available treatment choices, highlighting the significance of comprehending the disease's complexities and investigating cutting-edge strategies to enhance patient outcomes.

The cells of the ovaries, which are the female reproductive organs in charge of creating eggs and hormones, give birth to ovarian cancer. It includes a diverse range of cancers with various histological subtypes and clinical manifestations. 90% of instances of ovarian cancer are of the epithelial variety, which is then followed by germ cell tumors and sex cord-stromal tumors [2].

Ovarian cancer has a multifaceted etiology that is influenced by intricate interactions between genetic, hormonal, and environmental variables. Because ovarian cancer incidence rises with age, especially after menopause, advanced age is a significant risk factor [3]. Additionally important is family history; those who have a first-degree relative who has the disease are at higher risk [4]. A higher risk of developing ovarian cancer is also significantly linked to specific genetic abnormalities, such as BRCA1 and BRCA2 [5].

Ovarian cancer is caused by complex molecular changes, including genetic and epigenetic modifications. Mutations in important oncogenes like KRAS and tumor suppressor genes like TP53 disturb cellular homeostasis, which promotes unchecked cell growth and tumor development. Tumor development and metastasis are further aided by the dysregulation of several signaling pathways, including the PI3K/AKT and Wnt/-catenin pathways [6].

Clinically, ovarian cancer frequently exhibits vague signs such bloating in the abdomen, pain in the pelvis, and modifications in bowel or bladder habits. The majority of cases are detected at advanced stages, when the illness has already progressed outside the ovaries, as a result of

13535

these ambiguous symptoms contributing to diagnostic delays [7]. Accurate diagnosis and early detection are essential for enhancing patient outcomes.

Recent developments in imaging methods and the discovery of biomarkers like CA-125 and HE4 have given doctors effective diagnostic tools for ovarian cancer. High sensitivity and specificity for early detection remain challenging, albeit [8]. The variability of ovarian cancer also makes it difficult to design tailored treatment plans and targeted medicines.

With a focus on important topics such epidemiology, risk factors, etiology, clinical presentation, diagnosis, and treatment, this study seeks to give a thorough overview of ovarian cancer. This review seeks to increase understanding of ovarian cancer and provide direction for next research and clinical practice by synthesizing the existing knowledge and emphasizing recent developments and active research projects.

Epidemiology and Risk Factors

Worldwide, there is a large amount of variance in the incidence rates of ovarian cancer, with variations seen across various racial and ethnic groups. For early detection, prevention, and focused interventions, it is crucial to comprehend the epidemiological characteristics and risk factors connected to ovarian cancer.

1. Incidence and Global Variation: Ovarian cancer is one of the most prevalent gynecological malignancies and is associated with significant morbidity and mortality in female patients. Globally, there are different incidence rates, with wealthier nations reporting higher rates than less developed areas [1]. These variances are influenced by a number of variables, including access to healthcare, lifestyle, reproductive habits, and genetic predisposition.

2. Age and Reproductive Factors: Ovarian cancer incidence rises steadily with age, especially after menopause [2]. Advanced age is a substantial risk factor for the disease. Reproductive variables also have an impact; for example, nulliparity (never having given birth) and late age at first delivery are linked to a higher risk [3]. Menarche (the start of menstruation) at a young age and menopause at an advanced age have both been linked to risk factors.

3. Family History and Genetic propensity: A fraction of ovarian cancer cases have been found to have a substantial familial propensity. A person's risk is increased [4] if they have a first-degree relative (mother, sister, or daughter) who has the disease. A considerable majority of instances of hereditary ovarian cancer are caused by mutations in particular

13536

Eur. Chem. Bull. 2023, 12(Special Issue 4), 13534-13545

genes, such as BRCA1 and BRCA2 [5]. Along with Lynch syndrome and Peutz-Jeghers syndrome, other genetic abnormalities can increase the risk of getting ovarian cancer.

4. Hormonal and Reproductive Factors: A variety of studies have linked various hormonal factors, such as the use of oral contraceptives, hormonal replacement treatment, and hormone-releasing intrauterine devices, to an increased risk of ovarian cancer [6]. Hormone replacement treatment may modestly raise the risk of ovarian cancer, especially with long-term use and combination therapy, although long-term use of oral contraceptives has been linked to a lower chance of acquiring the disease.

5. Environmental Exposures: The development of ovarian cancer has been linked to exposure to specific environmental variables. A modest elevated risk has been linked to the usage of talcum powder in the vaginal area [7-10]. Ovarian cancer risk may also be increased by occupational exposures like asbestos exposure.

For focused screening programs, risk assessment, and preventative efforts, it is essential to understand the epidemiology and risk factors related to ovarian cancer. Women who are at risk for ovarian cancer can benefit from early identification and better outcomes by identifying high-risk populations and putting appropriate measures in place.

Pathogenesis of Ovarian Cancer

The development and spread of the disease are fueled by a complex interplay of genetic, molecular, and cellular abnormalities that make up the ovarian cancer pathogenesis. To find new therapy targets and enhance patient outcomes, it is essential to comprehend the underlying mechanisms.

1. Genetic and epigenetic alterations: Genetic changes are a major factor in the development of ovarian cancer. Key tumor suppressor gene mutations, including those in TP53, BRCA1, and BRCA2, are frequently seen in both inherited and sporadic cases [11]. These mutations affect these genes' ability to operate normally, which weakens their capacity to repair DNA and increases genomic instability. The disruption of gene expression patterns in ovarian cancer cells is further exacerbated by epigenetic modifications such as DNA methylation and histone modifications [12].

2. Signaling Channel Dysregulation: The proliferation, survival, and differentiation of cells are all governed by a number of signaling pathways that are dysregulated in ovarian cancer.

13537

The PI3K/AKT/mTOR pathway, which controls cell growth and metabolism, is one of the most commonly changed pathways [13]. This pathway's activation encourages cell survival and apoptosis resistance. Additionally, ovarian cancer frequently exhibits dysregulation of the Wnt/-catenin pathway, which is important for cellular growth and tissue homeostasis [14-17].

3. Tumor Microenvironment: The tumor microenvironment is crucial to the development and spread of ovarian cancer. Cancer cells interact with stromal cells, immune cells, and extracellular matrix elements to promote angiogenesis, immunological evasion, and tumor invasion [15]. The development of medication resistance and the encouragement of tumor growth are both influenced by the interactions between cancer cells and their microenvironment.

4. Hormonal Factors: Estrogen and progesterone are two hormones that have been linked to the onset and spread of ovarian cancer. The expression of the progesterone receptor (PR) and the estrogen receptor (ER) in ovarian cancer cells affects the tumor's behavior and how it reacts to hormonal therapy [16]. The interaction of several molecular changes and hormonal signaling pathways throughout the etiology of ovarian cancer adds to its complexity.

For the creation of targeted medicines and individualized therapeutic strategies, it is essential to comprehend the complex molecular mechanisms underlying the pathogenesis of ovarian cancer. It could be able to enhance therapeutic results and defeat medication resistance in ovarian cancer by focusing on particular molecular changes and stymieing essential signaling pathways.

Clinical Presentation and Diagnosis

Ovarian cancer has a complex clinical presentation because of its vague symptoms and the lack of effective screening tools for early detection. Given that the majority of instances are only discovered in the later stages, early diagnosis is essential for enhancing patient outcomes. The clinical signs and symptoms of ovarian cancer are highlighted in this section along with the methods used to diagnose it.

1. Nonspecific Symptoms: Ovarian cancer frequently exhibits nonspecific signs and symptoms that are simple to ignore or mistake for other benign illnesses. Bloating in the abdomen, pelvic pain or pressure, bowel pattern alterations, urine urgency or frequency, and

13538

Eur. Chem. Bull. 2023, 12(Special Issue 4), 13534-13545

unexplained weight loss are typical symptoms [18]. These ambiguous symptoms add to diagnostic delays, which result in advanced disease when patients appear.

2. Imaging Techniques: The evaluation of ovarian masses and the staging of ovarian cancer both heavily rely on imaging. Transvaginal ultrasonography (TVUS), which allows for thorough observation of the ovaries and evaluation of the features of ovarian masses [12], is usually utilized as an initial imaging modality. Further analysis is conducted using magnetic resonance imaging (MRI) and computed tomography (CT) scans, particularly when determining the extent of the tumor, the involvement of the lymph nodes, and the presence of metastases.

3. Biomarkers: A number of biomarkers have undergone research to determine their applicability in the detection and follow-up of ovarian cancer. The most well investigated biomarker is a glycoprotein called CA-125, and it is increased in most epithelial ovarian malignancies [3]. However, because it can also be high in benign gynecological diseases and other cancers, CA-125 lacks specificity. Inhibin, human epididymis protein 4, and other biomarkers have showed potential when used with CA-125 to increase diagnostic precision [14].

4. Risk-Reducing techniques: To lessen the burden of the disease in people who have a high risk of getting ovarian cancer, risk-reducing techniques may be used. Women with BRCA1 or BRCA2 mutations or those with a significant family history of ovarian cancer are advised to undergo risk-reducing bilateral salpingo-oophorectomy (RRBSO), a surgical procedure that involves the removal of the fallopian tubes and ovaries [15]. This preventative procedure can be thought about after childbearing is finished because it considerably lowers the danger of ovarian cancer developing.

Ovarian cancer detection remains difficult in terms of accuracy and timeliness. In order to improve early detection and distinguish between benign and malignant ovarian masses, efforts are currently being made to develop novel diagnostic tools, such as the identification of additional biomarkers and the incorporation of genetic profiling techniques.

Treatment Options for Ovarian Cancer

A multimodal strategy is used to manage ovarian cancer, using different treatment modalities based on the patient's unique circumstances, the disease's stage, and its histological subtype.

13539

The treatment options for ovarian cancer are covered in this part, which also emphasizes new developments in therapeutic approaches.

1. Surgery: Surgery is a key component of ovarian cancer treatment. Complete tumor resection, which involves removing the uterus, fallopian tubes, ovaries, and nearby lymph nodes, is the main objective of surgery [19]. Aiming for minimum residual disease after cytoreductive surgery has been linked to better survival results. Women of childbearing age with early-stage illness may be candidates for fertility-sparing surgery in specific circumstances.

2. Chemotherapy is an essential component of the treatment of ovarian cancer and is given either as adjuvant therapy after surgery or as neoadjuvant therapy before surgery. Common chemotherapy regimens consist of a taxane (paclitaxel or docetaxel) and a platinum drug (cisplatin or carboplatin), respectively [20]. Chemotherapy seeks to get rid of any remaining cancer cells and stop the disease from coming back. Intraperitoneal chemotherapy, which delivers the medications directly into the abdominal cavity, is one recent development that has improved outcomes for some patients.

3. Targeted medicines: Development of targeted medicines is a result of improvements in our knowledge of the molecular changes that underlie ovarian cancer. Olaparib and niraparib are two poly (ADP-ribose) polymerase (PARP) inhibitors that have significantly improved the therapeutic choices for ovarian cancer in people with BRCA1/2 mutations. These drugs have shown considerable clinical effects and target particular weaknesses in cancer cells.

4. Immunotherapies: Immunotherapy has shown promise in the fight against ovarian cancer. Immune checkpoint drugs, which disrupt the programmed cell death protein 1 (PD-1) pathway and include pembrolizumab and nivolumab, have demonstrated activity in some subsets of ovarian cancer patients [4]. The effectiveness of combination methods, such as using immune checkpoint inhibitors with other targeted medications or chemotherapy, is now being studied in clinical trials.

5. Maintenance Therapy and Recurrent Disease: The goal of maintenance therapy is to sustain remission and slow the course of the disease [15]. It often entails continuing to administer chemotherapy or targeted medicines after the conclusion of initial treatment. Treatment options for recurrent or chronic disease include more surgery, different

13540

chemotherapy regimens, targeted medicines, and enrollment in clinical trials testing novel medications or treatment combinations.

The changing landscape of ovarian cancer treatment stresses the value of a multidisciplinary, individualized strategy that takes into account the unique patient's characteristics and tumor biology. To further enhance outcomes for ovarian cancer patients, future research will look for predictive biomarkers, address drug resistance, and investigate innovative therapeutic approaches.

Emerging Trends and Future Directions

Research on ovarian cancer is still being conducted, and efforts are also being made to find new methods for the disease's early diagnosis, enhance patient outcomes, and improve overall management. In terms of ovarian cancer research and clinical practice, this section highlights some of the current trends and potential future paths.

1. Molecular profiling and precision medicine The molecular landscape of ovarian cancer has been better understood thanks to developments in molecular profiling methods like next-generation sequencing. This information has paved the door for treatment plans that are specifically tailored to each tumor's specific genetic abnormalities [1]. The possibility of customizing treatment choices and discovering new therapeutic targets lies in the integration of molecular profiling into ordinary clinical practice.

2. Immunotherapy and Combination Approaches: Research is ongoing to fully utilize the immune system's potential in the treatment of ovarian cancer. Immunotherapy has showed promise in a number of cancer types. Immune checkpoint inhibitors may be used with other targeted therapies, chemotherapy, or vaccinations to improve response rates and combat resistance [2]. Additionally, there is considerable potential for the development of innovative immunotherapeutic strategies including chimeric antigen receptor (CAR) T-cell treatment and cancer vaccines.

3. Early Detection and Screening Techniques: Work is still being done to enhance ovarian cancer early detection and screening techniques. Exosomes and circulating tumor DNA are examples of novel biomarkers that may offer more precise and sensitive tools for disease progression monitoring and early diagnosis [3]. Additionally, the effectiveness and precision

13541

Eur. Chem. Bull. 2023, 12(Special Issue 4), 13534-13545

of screening programs may be improved by the incorporation of imaging modalities and artificial intelligence-based algorithms.

4. Aiming at the Tumor Microenvironment: The tumor microenvironment has a significant impact on the development of ovarian cancer and the effectiveness of treatment. Research is ongoing in the field of targeting the stromal cells, immune cells, and angiogenesis that make up the tumor microenvironment [4]. The creation of combination therapies is one of the strategies being investigated to alter the tumor microenvironment and improve the effectiveness of current treatments.

5. Patient Support and Survivorship: Patients with ovarian cancer are increasingly receiving attention for their psychosocial and supportive care needs. For women affected by ovarian cancer, efforts are being undertaken to improve patient support services, survivorship care, and quality of life. Comprehensive care models are incorporating supportive therapies that address mental wellbeing, symptom management, and survivorship issues.

In order to effectively combat the problems posed by ovarian cancer, more research must be conducted, and multidisciplinary teams must work together. Significant improvements can be made in the early identification, therapy, and general management of ovarian cancer by embracing emerging ideas, putting precision medicine approaches into practice, and concentrating on patient-centered care.

Conclusion

In conclusion, ovarian cancer continues to be a serious health issue for women all over the world, with significant morbidity and mortality. The pathophysiology, epidemiology, clinical presentation, diagnosis, treatment choices, and current trends in both research and clinical practice have all been thoroughly covered in this review study.

Ovarian cancer is caused by complex genetic and molecular changes that promote the growth and spread of tumors. For the purpose of locating possible therapeutic targets and enhancing patient outcomes, it is essential to comprehend these mechanisms. Ovarian cancer epidemiological variables and risk factors have been explored, emphasizing the value of early identification and prevention measures.

Ovarian cancer frequently has a vague clinical appearance, making early identification difficult. Biomarkers and imaging techniques, among other diagnostic methods, are crucial to

13542

its discovery. A multimodal approach is used in the treatment of ovarian cancer and includes surgery, chemotherapy, targeted treatments, and immunotherapies. Precision medicine and immunotherapy are two recent innovations that raise new hopes for better treatment results.

Molecular profiling, early detection techniques, focusing on the tumor microenvironment, and patient support are some of the new developments in ovarian cancer research. These areas have the potential to advance the discipline and improve patient care. In order to address the issues raised by ovarian cancer, this review paper highlights the importance of ongoing research, collaboration, and a multidisciplinary approach. We can make substantial progress in enhancing the prognosis and quality of life for women impacted by ovarian cancer by integrating novel approaches, enhancing early detection techniques, and customizing treatment options. It is our aim that this review paper will be a useful tool for researchers, doctors, and other healthcare workers working in the ovarian cancer sector, ultimately assisting in the creation of more efficient prevention, detection, and treatment plans.

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. PMID: 25220842.

2. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992 Nov 1;136(9):1184-203. doi: 10.1093/oxfordjournals.aje.a116499. PMID: 1476144.

3. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand. 2004 Jul;83(7):783-95. doi: 10.1111/j.0001-6349.2004.00473.x. PMID: 15225198.

4. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117-30. doi: 10.1086/375033. Epub 2003 Apr 15. PMID: 12677558; PMCID: PMC1180275.

5.   Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112. PMID: 28632866; PMCID: PMC5817531.

6.   Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008 Jan 26;371(9609):303-14. doi: 10.1016/S0140-6736(08)60167-1. PMID: 18294997; PMCID: PMC3652196.

7.   Terry KL, Karageorgi S, Shvetsov YB, et al. Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013 Jun;6(6):811-21. doi: 10.1158/1940-6207.CAPR-13-0037. Epub 2013 Apr 19. PMID: 23604081; PMCID: PMC3693124.

8.   Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014 Apr;124(1):1-5. doi: 10.1016/j.ijgo.2013.10.001. PMID: 24355409.

9.   Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016 Mar;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011. Epub 2016 Feb 1. PMID: 26836326; PMCID: PMC4813652.

10.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8. PMID: 31912902.

11.   Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009 Oct;9(6):415-28. doi: 10.1038/nrc2644. PMID: 19404386; PMCID: PMC2849635.

12.   Menon U, Karpinskyj C, Gentry-Maharaj A, et al. Ovarian cancer prevention and screening. Obstet Gynecol. 2018 Feb;131(2):397-410. doi: 10.1097/AOG.0000000000002462. PMID: 29324605.

13.   American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021.

13544

Eur. Chem. Bull. 2023, 12(Special Issue 4), 13534-13545

14.   Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12. doi: 10.1001/jama.291.22.2705. PMID: 15187053.

15.   Prat J; FIGO Committee on Gynecologic Oncology. Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO). Obstet Gynecol. 2015;126(1):171-174. doi:10.1097/AOG.0000000000000917.

16.   Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996 May;14(5):1545-51. doi: 10.1200/JCO.1996.14.5.1545. PMID: 8622069.

17.   du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers

18.   Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007;106(1):69-74. doi:10.1016/j.ygyno.2007.02.026

19.   Norbeck A, Asp M, Carlsson T, Kannisto P, Malander S. Age and Referral Route Impact the Access to Diagnosis for Women with Advanced Ovarian Cancer. J Multidiscip Healthc. 2023;16:1239-1248. Published 2023 May 3. doi:10.2147/JMDH.S401601

20.   Reijonen M, Holopainen E, Arponen O, et al. Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer. BMC Cancer. 2023;23(1):299. Published 2023 Apr 1. doi:10.1186/s12885-023-10760-2

13545

Eur. Chem. Bull. 2023, 12(Special Issue 4), 13534-13545